Hikma Pharmaceuticals Plc (LON:HIK) was downgraded by analysts at Stifel Nicolaus to a “hold” rating in a research note issued to investors on Tuesday. They presently have a GBX 1,320 ($17.07) price target on the stock, down from their prior price target of GBX 2,300 ($29.75). Stifel Nicolaus’ target price points to a potential upside of 2.48% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,500 ($19.40) target price (down previously from GBX 1,800 ($23.28)) on shares of Hikma Pharmaceuticals Plc in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) lowered Hikma Pharmaceuticals Plc to a “neutral” rating and cut their target price for the company from GBX 2,600 ($33.63) to GBX 1,310 ($16.94) in a research note on Tuesday, August 22nd. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 1,560 ($20.18) price target on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 17th. HSBC Holdings plc dropped their price target on Hikma Pharmaceuticals Plc from GBX 1,700 ($21.99) to GBX 1,410 ($18.24) and set a “reduce” rating on the stock in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC reaffirmed an “underperform” rating and set a GBX 1,450 ($18.75) price target on shares of Hikma Pharmaceuticals Plc in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 1,574.18 ($20.36).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1294.00 on Tuesday. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,101.00 and a 12 month high of GBX 2,346.00. The stock’s market cap is GBX 3.11 billion. The company has a 50 day moving average price of GBX 1,345.28 and a 200-day moving average price of GBX 1,733.12.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/stifel-nicolaus-lowers-hikma-pharmaceuticals-plc-hik-to-hold/1529100.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.